Should I buy AbbVie (ABBV) stock or is it too late?
⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (239 calls tested). It aims for $300 (+16 %), call made on July 14, 2026, maturing on July 14, 2027 (45 d ago).
Firm-by-firm track record on AbbVie
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| RBC Capital | 100 % | +27.8 % | 6 | $280 +8% |
| UBS | 100 % | +24.3 % | 9 | $260 +1% |
| JP Morgan | 80 % | +19.2 % | 5 | $280 +8% |
| Raymond James | 100 % | +18.5 % | 8 | $250 -3% |
| Piper Sandler | 93 % | +16.8 % | 14 | $303 +17% |
| Citigroup | 100 % | +16.7 % | 14 | $260 +1% |
| Evercore ISI Group | 80 % | +15.9 % | 5 | $260 +1% |
| Guggenheim | 90 % | +13.6 % | 10 | $288 +12% |
✅ Reasons to believe
- 81% of analysts rate it a buy (Buy consensus, 16 ratings) — a sign of market conviction.
- Median price target $283, i.e. +9% from the current price ($258).
- The most reliable firm on ABBV, RBC Capital (100% hit rate, 6 scored calls), targets $280 (call made on July 10, 2026, maturing on July 10, 2027) (+8%) in its most recent call, and $260 (call made on February 25, 2026, maturing on February 25, 2027) (+1%) in the one coming due soonest.
- 9 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
- Pays a dividend (2.7% yield), raised for 12 years — regular income on top of potential upside.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 16 ratings, 3 are neutral.
- High valuation (P/E ~74): strong growth is already "priced in", leaving little room for error.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on ABBV
Median target $283 (+9%) · 16 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in AbbVie now?
We won't decide for you. The facts: 81% of analysts rate it a buy, median target $283 (+9%), and RBC Capital (most reliable on ABBV, 100%) targets $280. Weigh that against valuation (P/E ~74). This is not personalized advice.
Is it too late to invest in AbbVie?
Not according to analysts: the median target ($283) is still +9% above the current price ($258) (most reliable on ABBV: RBC Capital, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is AbbVie still worth investing in?
It depends on the gap between the price ($258) and its estimated value: analysts target $283 on median (+9%), with 81% buys (most reliable on ABBV: RBC Capital, 100%). Cross-check with their real reliability on ABBV and the cautions above. Information, not advice.
What's the main risk in buying ABBV?
The consensus is not unanimous: of 16 ratings, 3 are neutral.
→ Go deeper: the full AbbVie profile (consensus, analyst reliability, price target, performance).